

FDA and Industry GDUFA II Implementation Quarterly Meetings – 4Q2019 Meeting
October 15, 2019, 1:30 PM – 3:30 PM
FDA White Oak Campus, Silver Spring, MD
Building 32, Room 1211

Agenda

- Ground Rules and Guiding Principles of Implementation Meetings (FDA Led)
- Outstanding Items from FY 2019 (Industry Led)
- Imminent Approval Position Paper (Industry Led)

Participants

<u>FDA:</u>		<u>Industry:</u>	
Tiana Barnes	CDER	Rafael Antunes	EFCG (Hovione)
Ashley Boam	CDER	Joel Carpenter	BPTF (Albermarle)
Sally Choe	CDER	John DiLoreto	BPTF
Mary Beth Clarke	CDER	David Gaugh	AAM
Alonza Cruse	ORA	Kiran Krishnan	AAM (Apotex)
Michael Kopcha	CDER	Lisa Parks	AAM
Ellen Morrison	ORA	Cornell Stamoran	PBOA (Catalent)
Donal Parks - SME	CDER	Chuck Stankovic	BPTF (Piramal)
Joy Scott	CDER	Wayne Talton	AAM (Mylan)
Maryll Toufanian	CDER	Scott Tomsy	AAM (Teva)
Susan Zuk - SME	CDER	Bethany Walls	BPTF (MilleporeSigma)
		Elizabeth White	EFCG (Evonik)

Ground Rules and Guiding Principles of Implementation Meetings

FDA led a discussion on ground rules and guiding principles to establish protocols for addressing Industry concerns and issues.

Outstanding Items from FY2019

Industry and FDA discussed, provided clarity, and closed out several outstanding GDUFA II Implementation issues that arose during FY2019.

Imminent Approval Position Paper

Industry presented a position paper to FDA on Imminent Approval. FDA commented that further discussion would be needed before any feedback could be provided.